Vera Therapeutics (VERA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Effective January 29, 2024, the Company halted its at-the-market offering of Class A common stock and terminated the associated prospectus under the 2022 Sales Agreement with Cowen and Company, LLC. The agreement remains in effect, but no stock sales will occur until a new prospectus or registration is filed. The company’s current report includes forward-looking statements about its financial estimates, which are speculative and subject to change due to inherent risks and uncertainties.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.